35709-76-3 Usage
Uses
Used in Organic Synthesis:
N-(2,3-dimethyl-phenyl)-4-nitro-benzamide is used as a building block for the synthesis of various pharmaceuticals and biologically active molecules, contributing to the development of new drugs and chemical compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-(2,3-dimethyl-phenyl)-4-nitro-benzamide is utilized as a key component in the design and synthesis of novel drug candidates, targeting specific therapeutic areas.
Used in Pharmaceutical Industry:
N-(2,3-dimethyl-phenyl)-4-nitro-benzamide is used as an intermediate in the production of pharmaceuticals, playing a crucial role in the development of new medications with potential therapeutic benefits.
Used in Pharmacological Research:
N-(2,3-dimethyl-phenyl)-4-nitro-benzamide is investigated for its potential pharmacological activities, such as anti-inflammatory and analgesic effects, which could lead to the discovery of new treatments for various medical conditions.
Used in Coordination Chemistry:
N-(2,3-dimethyl-phenyl)-4-nitro-benzamide has been studied for its potential use as a ligand in coordination chemistry, which could result in the development of new materials with unique properties and applications.
Used in Analytical and Biochemical Research:
N-(2,3-dimethyl-phenyl)-4-nitro-benzamide has been explored as a fluorescent probe in analytical and biochemical research, which may contribute to advancements in the detection and analysis of various biological processes and molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 35709-76-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,7,0 and 9 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 35709-76:
(7*3)+(6*5)+(5*7)+(4*0)+(3*9)+(2*7)+(1*6)=133
133 % 10 = 3
So 35709-76-3 is a valid CAS Registry Number.
35709-76-3Relevant academic research and scientific papers
Schlitzer, Martin,Sattler, Isabel,Dahse, Hans-Martin
, p. 2037 - 2045 (1999)
Several CAAX-peptidomimetics were linked to homofarnesoic acid via a β-alanyl spacer with the intention to obtain a novel type of bisubstrate analogue farnesyltransferase inhibitors. However, the compounds were found to be only weakly active in the farnesyltransferase inhibition assay. Nevertheless, they displayed antiproliferative activity against different tumor cell lines in the low micromolar range. Replacement of the β-alanine moiety by aspartic acid-1-methyl ester resulted in a compound which inhibited the farnesyltransferase with an IC50 of 860 nM. The corresponding free acid showed a eightfold loss in activity (IC50 = 6.9 μM).
